Lerivon (Mianserin Hydrochloride)

Lerivon, a tetracyclic antidepressant, is employed in the treatment of depressive disorders.

• Major depressive disorder: improves mood, sleep, and overall functional capacity.
• Depressive symptoms: reduces severity of depressive episodes and associated anxiety.
• Psychiatric depressive states: supports remission when incorporated into a comprehensive treatment plan.

• Mianserin hydrochloride acts primarily as an antagonist of central presynaptic α2‑adrenergic receptors, which enhances norepinephrine release. It also blocks several serotonin receptors (including 5‑HT2 and 5‑HT3), leading to increased serotonergic neurotransmission. These combined actions elevate monoamine levels in the brain, contributing to its antidepressant effect.

Lerivon may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Drowsiness: feeling unusually sleepy or fatigued.
• Dry mouth: reduced salivation causing discomfort.
• Constipation: infrequent or difficult bowel movements.
• Weight gain: increase in body weight over time.
• Dizziness: sensation of light‑headedness, especially when standing.
• Increased appetite: heightened desire for food.

Serious or Rare Side Effects

• Agranulocytosis: severe reduction in white blood cells, increasing infection risk.
• Seizures: occurrence of convulsive episodes.
• Severe hypotension: marked drop in blood pressure leading to fainting.
• Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening.
• Hepatic dysfunction: liver enzyme abnormalities indicating possible liver injury.
• Neutropenia: lowered neutrophil count, compromising immune defense.

Before initiating Lerivon therapy, clinicians should consider several safety measures.

• Monitor blood pressure: check regularly due to risk of orthostatic hypotension.
• Assess liver function: use caution in patients with hepatic impairment.
• Evaluate for suicidal ideation: observe closely during early treatment phases.
• Avoid abrupt discontinuation: taper the dose to prevent withdrawal symptoms.
• Review concomitant medications: consider potential drug‑drug interactions.
• Store at ambient temperature: keep in the original container, protect from moisture.

Lerivon can interact with various medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
• Selective serotonin reuptake inhibitors (SSRIs): potential serotonin syndrome.
• Central nervous system depressants: may cause excessive sedation.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: additive blood‑pressure‑lowering effect.
• Anticholinergic drugs: may intensify dry‑mouth symptoms.
• CYP2D6 inhibitors: can increase mianserin plasma concentrations.